NEJM· Luke J. LaffinCleveland Clinic Coordinating Center for Clinical Research, ClevelandStephen J. NichollsVictorian Heart Institute, Melbourne, VIC, AustraliaRussell S. ScottNew Zealand Clinical Research, Christchurch, New ZealandPeter M. CliftonRoyal Adelaide Hospital, Adelaide, SA, AustraliaRenate KoopsAotearoa Clinical Trials, Auckland, New ZealandAshish SarrajuCleveland Clinic Coordinating Center for Clinical Research, ClevelandShweta SinghCRISPR Therapeutics, BostonQiuqing WangKathy WolskiCleveland Clinic Coordinating Center for Clinical Research, ClevelandHuansheng XuJen NielsenNaimish PatelJason M. DuranCRISPR Therapeutics, BostonSteven E. NissenCleveland Clinic Coordinating Center for Clinical Research, Cleveland·· 2026-08-28AI 评分52
NEJM发表CTX310靶向ANGPTL3的CRISPR-Cas9基因编辑持久性数据
Durability of CRISPR-Cas9 Gene Editing Targeting ANGPTL3 with CTX310
AI 导读
NEJM发表CTX310（CRISPR-Cas9基因编辑靶向ANGPTL3）的持久性数据，作者来自Cleveland Clinic等机构及CRISPR Therapeutics。
来源：NEJM · nejm.org